CD274 and neoplasm: Subsequently, keynote 010 further proved that compared with docetaxel, PD-L1 positive (tumor proportion score, TPS ≥ 1%) patients could gain significantly survival benefits from pembrolizumab, especially those with TPS ≥ 50%, and the incidence of adverse reactions was lower [10].